	US 12,144,866 B2
	Transferrin binding antibodies and use thereof
Zhaozhong Han, Shanghai (CN); Hongya Pan, Shanghai (CN); and Mengfan Peng, Shanghai (CN)
Assigned to LINNO PHARMACEUTICALS INC., Shanghai (CN)
Filed by LINNO PHARMACEUTICALS INC., Shanghai (CN)
Filed on Jun. 1, 2023, as Appl. No. 18/327,091.
Application 18/327,091 is a continuation of application No. PCT/CN2021/135059, filed on Dec. 2, 2021.
Prior Publication US 2024/0131177 A1, Apr. 25, 2024 Prior Publication US 2024/0226315 A9, Jul. 11, 2024
Int. Cl. A61K 47/68 (2017.01); C07K 16/18 (2006.01)

CPC A61K 47/6843 (2017.08) [A61K 47/6811 (2017.08); A61K 47/6829 (2017.08); C07K 16/18 (2013.01); C07K 2317/569 (2013.01)]

13 Claims

1. A transferrin-binding protein, comprising:

a VHH or a transferrin-binding fragment thereof,

wherein VHH comprises CDR1, CDR2 and CDR3,

wherein the CDR1 comprises the amino acid sequence of SEQ ID NO: 1,

wherein the CDR2 comprises the amino acid sequence of SEQ ID NO: 22, and

wherein the CDR3 comprises the amino acid sequence of SEQ ID NO: 45.